Indian Journal of Pharmaceutical Sciences
Users online: 70
Scientific Publication of the Indian Pharmaceutical Association
Home Email this page Print this page Bookmark this page Decrease font size Default font size Increase font size
The Journal Search Current Issue Archives Instructions Online submission Login  


 
SHORT COMMUNICATION
Year : 2007  |  Volume : 69  |  Issue : 1  |  Page : 154-157
Development of a HPLC method for the simultaneous determination of losartan potassium and atenolol in tablets


Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Annamalai Nagar-608 002, India

Date of Submission17-Nov-2005
Date of Decision26-Jun-2006
Date of Acceptance21-Feb-2007

Correspondence Address:
T Sivakumar
Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Annamalai Nagar-608 002
India
Login to access the Email id


DOI: 10.4103/0250-474X.32137

Get Permissions

   Abstract 

A new reversed-phase high performance liquid chromatography method was developed and validated for the simultaneous determination of losartan potassium and atenolol in tablets. The separation was achieved on Supelcosil ODS analytical column (250.46 cm, i.d., 5 m) using acetonitrile and 25 mM potassium dihydrogen phosphate (45:55 v/v, pH 3.000.05) as mobile phase at a flow rate of 1.2 ml/min. Detection was carried out using a UV detector at 227 nm. The method was validated. The developed and validated method was successfully applied for the quantitative analysis of Losar beta tablets. The total chromatographic analysis time per sample was about 6 min with atenolol, chlorzoxazone (internal standard) and losartan eluting at retention times of about 2.72, 4.89 and 5.61 min, respectively. The standard curves were linear over the concentration ranges, 1 to 10 g/ml for losartan potassium and atenolol. The values obtained of LODs were 0.029 and 0.062 g/ml and LOQs were 0.078 and 0.187 g/ml for losartan potassium and atenolol, respectively. The proposed method is fast, accurate and precise for the determination of losartan potassium and atenolol for routine quality control of tablets containing these two drugs.



How to cite this article:
Sivakumar T, Venkatesan P, Manavalan R, Valliappan K. Development of a HPLC method for the simultaneous determination of losartan potassium and atenolol in tablets. Indian J Pharm Sci 2007;69:154-7

How to cite this URL:
Sivakumar T, Venkatesan P, Manavalan R, Valliappan K. Development of a HPLC method for the simultaneous determination of losartan potassium and atenolol in tablets. Indian J Pharm Sci [serial online] 2007 [cited 2014 Oct 21];69:154-7. Available from: http://www.ijpsonline.com/text.asp?2007/69/1/154/32137


Losartan potassium, a potassium salt of 2-Butyl-4-chloro-1-[[2-(1H-tetrazol-5-yl) [1,1-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol [Figure - 1], represents the first of a new class of orally active non-peptide angiotensin II (Type AT 1 ) receptor antagonists employed in the management of essential hypertension[1],[2]. The individual determination of losartan has been carried out in tablets by HPLC, capillary electrophoresis and super-critical fluid chromatography[3], in bulk and solid dosage forms by colorimetric method[4], simultaneously with its degradates in stressed tablets by LC-MS/MS[5] and HPTLC[6] and with its active metabolite in biological fluids by HPLC[7],[8],[9].

Atenolol, 4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy] benzeneacetamide [Figure - 1] is a selective β 1 -adrenoceptor antagonist[10] applied in the treatment of numerous cardiovascular disorders such as hypertension and angina pectoris. Several analytical methods reported for the quantitative determination of atenolol individually in pharmaceutical formulations or in biological fluids, are HPLC[11],[12],[13], gas chromatography[14], capillary zone electrophoresis[15], titrimetry[16] and spectrophotometry[17].

In recent years, these two drugs are successfully used in association in the treatment of hypertension and the pharmaceutical preparations containing both drugs have been marketed, permitting once a day administration. Although, many methods have been reported in the literature for the estimation of losartan potassium and atenolol individually, there is no single method reported for its simultaneous estimation. However, as the use of this preparation is increasing rapidly, it is very much essential to develop a suitable analytical method for the simultaneous estimation of losartan potassium and atenolol in its pharmaceutical forms. Such method should be simple, rapid, accurate and precise to be applied for routine quality control analysis, dissolution or similar studies. Hence, in the present study, a new reversed-phase high performance liquid chromatography method was developed and validated for the simultaneous determination of losartan potassium and atenolol in tablets.

Losartan potassium and atenolol were kindly gifted by Alembic Chemical Works, Vadodara, India. Chlorzoxazone (internal standard) was purchased from Madras Medical Company, Chennai, India. The commercially available Losar beta tablets (containing losartan potassium-50 mg and atenolol-50 mg) were obtained from Unichem Laboratories Ltd., Mumbai, India. Acetonitrile and methanol were of HPLC grade while buffer salts and all other reagents employed were of analytical reagent grade supplied by M/S S. D. Fine Chemicals, Mumbai, India. The HPLC grade water was prepared by using Milli-Q Academic, Millipore, Bangalore, India.

The analysis were performed on a Shimadzu chromatographic system (Japan), equipped with an LC-10 AD vp solvent delivery Module, SPD-10A UV-Visible detector, and a Rheodyne model 7125 injector valve fitted to a 20 l volume sample loop. Losartan potassium, atenolol and chlorzoxazone (internal standard) were resolved on a Supelcosil ODS analytical column (250.46 cm i.d., 5 m) in the reversed-phase partition chromatographic condition. The mobile phase composed of acetonitrile and 25 mM potassium dihydrogen phosphate (45:55 v/v, pH 30.05). The flow rate was 1.2 ml/min and the analytes and internal standard monitored at 227 nm. The HPLC system was controlled by a PC workstation with Shimadzu chromatographic software (CLASS LC 10, Ver.1.63) installed. The system was used in an air-conditioned HPLC laboratory atmosphere (202). Before the analysis, the mobile phase was degassed using Branson sonicator (Branson Ultrasonics Corporation, USA) and filtered through a 0.2 m membrane filter (Gelman Science, India). The system was equilibrated before making injection.

Stock solutions of losartan potassium, atenolol and chlorzoxazone (IS) were prepared individually by dissolving accurately weighed 10 mg of the drug in 10 ml of methanol. The prepared stock solution was stored at 4 protected from light. From this stock solution standard 100 g/ml was freshly prepared on the day of analysis.

Calibration standards for both the analytes were prepared individually from the standard solution of 100 g/ml by appropriate dilution with mobile phase by varying the losartan potassium concentration in the range 1, 2, 5, 7 and 10 g/ml (maintaining atenolol at 5.0 g/ml) and the atenolol concentration in the range 1, 2, 5, 7 and 10 g/ml (maintaining losartan potassium at 5.0 g/ml). An aliquot of the internal standard solution, after appropriate dilution, was added to each standard solution (final concentration, 2.5 g/ml). For the preparation of calibration curve for each analytes, an aliquot of 20 l of this calibration standard solutions were injected. Concentrations of 1, 5 and 10 g/ml were taken as quality control (QC) samples.

For estimating the tablet dosage form, 20 tablets from a batch were randomly selected and powdered. Amount equivalent to 25 mg each of losartan potassium and atenolol from powdered formulation were accurately weighed and taken in a 25 ml volumetric flask; suitable quantity of IS was added (final concentration, 2.5 g/ml) followed by 15 ml of methanol. The mixture was subjected to sonnication for 10 min for complete extraction of drugs, and the solution was made up to the mark with methanol. The solution was centrifuged at 4000 rpm for 10 min; the supernatant was taken and diluted with mobile phase (final concentration, 5 g/ml for each drug) and 20 l of this solution was injected for HPLC analysis.

Acetonitrile in different ratios (40 to 50%) in the mobile phase composed of 25 mM potassium dihydrogen phosphate at pH 3.00 were tested. The retention time of losartan potassium, atenolol and internal standard, chlorzoxazone decreased with increasing acetonitrile concentration in the mobile phase. The better separation and resolution of these drugs were obtained when the percentage of acetonitrile in the mobile phase was 45%, offering short run time of about 6 min.

The system suitability was assessed by six replicate analyses of the analytes at a concentration of 5.0 g/ml. The % CV of peak area and retention time for both drugs is ≤2. The efficiency of the column as expressed by number of theoretical plates for the six replicate injections was 44780.8 (mean% CV) and the USP tailing factor was 1.140.3 (mean% CV) for atenolol. The number of theoretical plates and the USP tailing factor for losartan potassium were found to be 94121.2 and 1.170.4, respectively.

Linearity was demonstrated at concentrations from 1 to 10 g/ml for both the analytes. The mean (SD) regression equation from six replicated calibration curves of losartan potassium and atenolol were y =0.3713 (0.0006) x +0.0074 (0.0284) and y =0.1675 (0.0009) x +0.0064 (0.0916) respectively. The correlation coefficients (R 2 ) were 0.9995 (0.0031) for losartan potassium and 0.9997 (0.0027) for atenolol, indicating a high degree of linearity for both losartan potassium and atenolol calibration curves. Limits of detection (LOD) and quantitation (LOQ) were estimated from the signal to noise ratio. The values obtained of LODs were 0.029 and 0.062 g/ml and LOQs were 0.078 and 0.187 g/ml for losartan potassium and atenolol, respectively.

The recovery was studied at concentrations of 50% (n=3), 100% (n=6) and 150% (n=3) of the target level in the tablet. In recovery studies, a known amount of analytes was spiked (dry addition) with a determined amount of placebo and the amount of each analyte recovered in relation to the added amount was calculated. The placebo used in this validation study contained the following inactive ingredients: lactose monohydrate, microcrystalline cellulose PH 101, corn starch, povidone, colloidal silicon dioxide, magnesium stearate and titanium dioxide. The recovery was found to be in the range of 99.95 to 100.42% which was well within the acceptance limit of 98 to102%.

Accuracy of the assay method was determined for both intra-day and inter-day variations using the replicate (n=6) analysis of the QC samples of 1, 5 and 10 g/ml. Accuracy and precision calculated for the QC samples during the intra-day and inter-day run are given in [Table - 1]. The intra-day accuracy ranged from -1.00 to 4.00% and precision from 0.741 to 1.040%. The inter-day accuracy ranged from 0.00 to 3.4% and precision from 1.335 to 1.881%. The intra-day and inter-day precisions were within the acceptance criteria of %CV ≤1.0 and ≤2.0, respectively.

The specificity study revealed the absence of excipients (placebo) interference since none of the peaks appears at the same retention time of losartan potassium, atenolol and chlorzoxazone peak [Figure - 2]. Hence it was concluded that the developed method is selective in relation to the excipient used in this study.

The stability of the analyte solutions were determined using losartan potassium and atenolol standard solution (5 g/ml) by keeping at ambient temperature for 48 h and analyzing. Stability studies indicated that the analytes were stable and are well within the acceptance level of 95%[18].

The developed and validated HPLC method was applied for the determination of losartan potassium and atenolol content in a commercial antihypertensive tablet, Losar beta. There was no interference of excipients in the product examined, so no addition extraction or separation procedures are required during their assay. The total chromatographic run time per sample was 6 min with atenolol, chlorzoxazone (internal standard) and losartan eluting at retention times of about 2.72, 4.89 and 5.61 min, respectively [Figure - 2]. The % recovery (meanS.D, n=6) was 100.020.21 for atenolol and 100.100.29 for losartan which were well within the acceptance limits of 95% to 105%.

The HPLC method described for the simultaneous determination of losartan potassium and atenolol has been found to be linear, precise, accurate and selective to be applied in routine and quality control analysis of tablets. In the proposed method, there are no additional extraction or separation procedures to extract the drug from the formulation excipient matrix thereby decreasing the error in quantitation.

 
   References Top

1.Smith, R.D., Chiu, A.T., Wong, P.C., Herblin, W.F. and Timmermans, P.B.M.W.M., Annu. Rev. Pharmacol. Toxicol., 1992, 32, 135.  Back to cited text no. 1    
2.Chiu, A.T., McCall, D.E. and Price, W.A., J. Pharmacol. Exp. Ther., 1990, 252, 71l.  Back to cited text no. 2    
3.Williams, R.C., Alasandro, M.S., Fasone, V.L., Boucher, R.J. and Edwards. J.F., J. Pharm. Biomed. Anal., 1996, 14, 1539.  Back to cited text no. 3    
4.Prabhakar, A. H. and Giridhar, R., J. Pharm. Biomed. Anal., 2002, 27, 861.  Back to cited text no. 4    
5.Zhao, Z.Z., Wang, Q., Tsai, E.W., Qin, X.Z. and Ip, D., J. Pharm. Biomed. Anal., 1999, 20, 129.  Back to cited text no. 5    
6.McCarthy, K.E., Wang, Q., Tsai, E.W., Gilbert, R.E. and Brooks, M.A., J. Pharm. Biomed. Anal., 1998, 17, 671.  Back to cited text no. 6    
7.Farthing, D., Sica, D., Fakhry, I., Pedro, A. and Gehr, T.W.B., J. Chromatogr. B, 1997, 704, 374.  Back to cited text no. 7    
8.Ritter, M.A., Furtek, C.I. and Lo, M.W., J. Pharm. Biomed. Anal., 1997, 15, 1021.  Back to cited text no. 8    
9.Yeung, P.K., Jamieson, A., Smith, G.J., Fice, D. and Pollak, P.T., Int. J. Pharm., 2000, 204, 17.  Back to cited text no. 9    
10.Wadworth, A.N., Murdoch, D. and Brogden, R.N., Drugs, 1991, 42, 468.  Back to cited text no. 10    
11.Pawlak, Z. and Clark, B.J., J. Pharm. Biomed. Anal., 1992, 10, 329.  Back to cited text no. 11    
12.Terry, S. and Teitelbaum, Z., J. Liq. Chromatogr., 1991, 1, 3735.  Back to cited text no. 12    
13.Lamprecht, G., Kraushofer, T., Stoschitzky, K. and Lindner, W., J. Chromatogr. B, 2000, 740, 219.  Back to cited text no. 13    
14.Peng, J.H., Tu, J.S. and Xin, J.D., J. China Pharm. Univer., 1995, 26, 344.  Back to cited text no. 14    
15.Shafaati, A. and Clark, B.J., J. Pharm. Biomed. Anal., 1996, 14, 1547.  Back to cited text no. 15    
16.Ebeid, M.Y., Moussa, B.A., A-Maleck, A. and Ashour, F.M., Egypt J. Pharm. Sci., 1997, 38, 171.  Back to cited text no. 16    
17.Prasad, U.V., Rao, G.V. and Sastry, C.S.P., Indian J. Pharm. Sci., 2002, 64, 129.  Back to cited text no. 17    
18.Lozano, P.P., Montoya, E.G., Orriols, A., Miρarro, M., Tic, J.R. and Negre J.M.S., J. Pharm. Biomed. Anal., 2004, 34, 979.  Back to cited text no. 18    


    Figures

  [Figure - 1], [Figure - 2]
 
 
    Tables

  [Table - 1]

This article has been cited by
1 An Improved HPLC Method for Simultaneous Analysis of Losartan Potassium and Hydrochlorothiazide with the Aid of a Chemometric Protocol
Miralem Smajic,Zorica Vujic,Nedad Mulavdic,Jasmina Brboric
Chromatographia. 2013; 76(7-8): 419
[Pubmed]
2 Simultaneous analysis of atorvastatin calcium and losartan potassium in tablet dosage forms by RP-HPLC and HPTLC
H. J. Panchal, B. N. Suhagia
Acta Chromatographica. 2010; 22(2): 173
[VIEW]
3 Formulation and evaluation of mouth dissolving tablets of losartan potassium by direct compression techniques
Kakade, S.M., Mannur, V.S., Ramani, K.B., Dhada, A.A., Naval, C.V., Bhagwat, A.
International Journal of Research in Pharmaceutical Sciences. 2010; 1(3): 290-295
[Pubmed]
4 Development and validation of new method for atenolol, hydrochlorothiazide and losartan potassium by RP-HPLC: Its application to routine quality control analysis
Kavitha, J., Muralidharan, S.
International Journal of ChemTech Research. 2010; 2(2)
[Pubmed]
5 Spectrophotometric and HPLC methods for simultaneous estimation of amlodipine besilate, losartan potassium and hydrochlorothiazide in tablets
Wankhede, S.B., Raka, K.C., Wadkar, S.B., Chitlange, S.S.
Indian Journal of Pharmaceutical Sciences. 2010; 72(1): 136-140
[Pubmed]
6 Simultaneous TLC-densitometric analysis of atenolol and lercanidipine hydrochloride in tablets
P. V. Deore, A. A. Shirkhedkar, S. J. Surana
Acta Chromatographica. 2008; 20(3): 463-473
[Pubmed]
7 Validation of UV spectrophotometric and HPLC methods for quantitative determination of atenolol in pharmaceutical preparations
Weich, A., De Oliveira, D.C., De Melo, J., Goebel, K., Rolim, C.M.B.
Latin American Journal of Pharmacy. 2007; 26(5): 765-770
[Pubmed]



 

Top
Print this article  Email this article
 
  Search
   
   Next article
   Previous article 
   Table of Contents
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (150 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed10363    
    Printed118    
    Emailed18    
    PDF Downloaded936    
    Comments [Add]    
    Cited by others 7    

Recommend this journal